A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
Clinical trial NCT06143735 · UNKNOWN
Trial details
- NCT number
- NCT06143735
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-31
- Primary completion
- 2024-12-31
- Enrollment
- 99
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.